Founder & CSO
Extensive scientific track record spanning 47 years with over 100 publications on African Trypanosomes, including pioneering studies on ApoL1 toxicity in these parasites.
Founder & CEO
Conceptualized and initially investigated ApoL1 as a therapeutic against human disease in 2010, with proven scientific track record of publications on ApoL1 toxicity.
Founder & Vice President R&D
Conceptualized targeting ApoL1 with a bispecific antibody guided system, bringing a strong background in bioinformatics, research study design, and data analysis.